Zacks Research Has Bullish Estimate for TEVA FY2024 Earnings

Teva Pharmaceutical Industries Limited (NYSE:TEVA) – Zacks Research increased their FY2024 EPS estimates for shares of Teva Pharmaceutical Industries in a note issued to investors on Monday, November 4th. Zacks Research analyst R. Department now expects that the company will earn $2.30 per share for the year, up from their prior estimate of $2.29. The consensus estimate for Teva Pharmaceutical Industries’ current full-year earnings is $2.33 per share. Zacks Research also issued estimates for Teva Pharmaceutical Industries’ Q4 2024 earnings at $0.67 EPS, Q3 2026 earnings at $0.79 EPS and FY2026 earnings at $2.77 EPS.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a research report on Monday, October 21st. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, October 17th. Barclays increased their target price on shares of Teva Pharmaceutical Industries from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 23rd. Finally, UBS Group upped their price target on shares of Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

Teva Pharmaceutical Industries Stock Up 0.4 %

Shares of TEVA opened at $17.50 on Thursday. Teva Pharmaceutical Industries has a 52 week low of $8.55 and a 52 week high of $19.31. The firm has a market cap of $19.83 billion, a P/E ratio of -44.87, a price-to-earnings-growth ratio of 1.34 and a beta of 0.87. The firm’s 50-day simple moving average is $17.98 and its 200 day simple moving average is $17.07. The company has a debt-to-equity ratio of 2.52, a quick ratio of 0.59 and a current ratio of 0.89.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Wednesday, November 6th. The company reported $0.67 EPS for the quarter, beating analysts’ consensus estimates of $0.63 by $0.04. Teva Pharmaceutical Industries had a negative net margin of 2.73% and a positive return on equity of 39.66%. The business had revenue of $4.33 billion for the quarter, compared to analyst estimates of $4.08 billion.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. New Covenant Trust Company N.A. bought a new position in shares of Teva Pharmaceutical Industries during the first quarter valued at $28,000. EntryPoint Capital LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the first quarter worth $30,000. UMB Bank n.a. increased its position in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after buying an additional 2,067 shares during the period. Beach Investment Counsel Inc. PA acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $48,000. Finally, Byrne Asset Management LLC acquired a new stake in shares of Teva Pharmaceutical Industries during the second quarter worth $52,000. Institutional investors own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.